Actively Recruiting
COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
Led by Peking Union Medical College Hospital · Updated on 2023-12-13
1224
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.
CONDITIONS
Official Title
COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who agree to participate and sign informed consent
- Male or female, 18 years or older
- Diagnosed with lung carcinoma by histological or cytological exams
- Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy, or targeted therapy
- History of confirmed COVID-19 infection
- Sufficiently functional organs
- Eastern Cooperative Oncology Group performance score between 0 and 2
You will not qualify if you...
- Life expectancy less than 3 months
- Less than 3 months since last confirmed COVID-19 infection
- Unable to return to hospital for follow-up
- Allergy to COVID-19 vaccine
- History of severe treatment-related adverse events graded 3 or higher related to antitumor therapies or immunization, except recoverable granulocytopenia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, China
Actively Recruiting
Research Team
M
Mengzhao Wang, MD
CONTACT
Y
Yan Xu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here